Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of a 9-valent recombinant HPV vaccine in Chinese men aged 18-45 years
CTR20242197Phase 3Active
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha) in human papillomavirus infection, anogenital warts, anal intraepithelial neoplasia (AIN), penile intraepithelial neoplasia (PeIN), anal cancer, sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Started Jul 2024; status: active.
02
Drugs
human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha)
03
Conditions
human papillomavirus infectionanogenital wartsanal intraepithelial neoplasia (AIN)penile intraepithelial neoplasia (PeIN)anal cancer
Beyond the preview
Go deeper on CTR20242197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242197.